Why Cytokinetics Stock Was a Nearly 5% Winner Today
This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...
Cytokinetics stock rises on Sanofi's rights acquisition
Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and ...
FierceBiotech1d
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...
Cytokinetics, Incorporated: Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...
Nasdaq15d
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
Corxel (formerly Ji Xing Pharmaceuticals) completed submission of the NDA for aficamten to treat obstructive HCM. The Center for Drug Evaluation of the National Medical Products Administration in ...
PMLiVE17d
Sanofi unveils plans to build €1bn insulin production base in China
Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China. The site, located in the Beijing Economic and Technological Development Zone, will be aimed at ...